Sangamo Therapeutics

Sangamo BioSciences is a clinical stage biotechnology company focused on translating science into genomic medicines using its platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company is focused on these therapeutic areas: inherited metabolic diseases, central nervous system diseases and inflammatory and autoimmune diseases. The company has an ongoing clinical trial evaluating SB-318 for the treatment of Mucopolysaccharidosis Type I. The company is also evaluating SB-FIX in a clinical trial which is designed to assess the SB-FIX in adults with severe hemophilia B. The company is evaluating ST-400 in a clinical trial to evaluate the adult subjects with beta-thalassemia.
  • TickerSGMO
  • ISINUS8006771062
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Wedbush Research

Wedbush Morning Call - May 26 2020 6:20AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Dave Nicoski ...
  • John Betz

Vermilion Compass: Weekly Equity Strategy

• Bullish but selective. As we alluded to last week, our long-term bullish outlook remains intact. However, looking through the charts we find a growing list of extended and parabolic patterns. While we continue to remain bullish, we acknowledge the likelihood of backing and filling, or a pause, is building. The further a stock's price action moves from its 200-day, the greater the possibility of a corrective reversion to the mean, or pullback. In last week's Compass our example was Boeing Corporation (BA). The stock is trading 40% above its 200-day moving average, and this rate of momentum i...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Wedbush Research

Wedbush Morning Call - May 26 2020 6:20AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - May 18 2020 6:54AM

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ResearchPool Subscriptions

Get the most out of your insights

Get in touch